| 1 |
Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi (Basel). 2019; 5(1): 26.
|
| 2 |
Prakash H, Ghosh AK, Rudramurthy SM, Singh P, Xess I, Savio J, et al. A prospective multicenter study on mucormycosis in India: epidemiology, diagnosis, and treatment. Med Mycol. 2019; 57(4): 395-402.
doi: 10.1093/mmy/myy060
pmid: 30085158
|
| 3 |
Skiada A, Pavleas I, Drogari-Apiranthitou M. Epidemiology and diagnosis of mucormycosis: an update. J Fungi (Basel). 2020; 6(4): 265.
|
| 4 |
Jeong W, Keighley C, Wolfe R, Lee WL, Slavin MA, Kong DM, et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019; 25(1): 26-34.
doi: 10.1016/j.cmi.2018.07.011
|
| 5 |
Reid G, Lynch JP 3rd, Fishbein MC, Clark NM. Mucormycosis. Semin Respir Crit Care Med. 2020; 41(1): 99-114.
|
| 6 |
Steinbrink JM, Miceli MH. Mucormycosis. Infect Dis Clin North Am. 2021; 35(2): 435-52.
doi: 10.1016/j.idc.2021.03.009
|
| 7 |
Safi M, Ang MJ, Patel P, Silkiss RZ. Rhino-orbital-cerebral mucormycosis (ROCM) and associated cerebritis treated with adjuvant retrobulbar amphotericin B. Am J Ophthalmol Case Rep. 2020;19: 100771.
|
| 8 |
Singh G, Vishnu VY. Neurological manifestations of rhino-oculo-cerebral mucormycosis in the COVID-19 era. Nat Rev Neurol. 2021;17: 657-8.
|
| 9 |
Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in Cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019; 19(12): e405-e421.
|
| 10 |
Panda S, Sahu MC, Turuk J, Pati S. Mucormycosis: a rare disease to notifiable disease. Braz J Microbiol. 2024; 55(2): 1065-81.
doi: 10.1007/s42770-024-01315-z
pmid: 38561499
|
Open Access 
)
